Pattern of multiple human papillomavirus infection and type competition: An analysis in healthy Chinese women aged 18–45 years

References

• Burd EM. Human papillomavirus laboratory testing: the changing paradigm. Clin Microbiol Rev. 2016;29(2):291–8. doi:10.1128/CMR.00013-15.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, Monsonego J, Franceschi S. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015;136(12):2752–2760. doi:10.1002/ijc.29082.
   PubMed Web of Science ®Google Scholar
• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670. doi:10.1002/ijc.30716.
   PubMed Web of Science ®Google Scholar
• Herrero R, Gonzalez P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015;16(5):e206–e216. doi:10.1016/S1470-2045(14)70481-4.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241–268.
   PubMedGoogle Scholar
• Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG, Chen W, Huang S-J, Zhao F-H, Li M-Q, et al. Efficacy, safety, and immunogenicity of an escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2020;112(2):145–153. doi:10.1093/jnci/djz074.
   PubMedGoogle Scholar
• Man I, Vänskä S, Lehtinen M, Bogaards JA. Human papillomavirus genotype replacement: still too early to tell? J Infect Dis. 2021;224(3):481–491. doi:10.1093/infdis/jiaa032.
   PubMed Web of Science ®Google Scholar
• Mesher D, Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JM, Chow EPF, Cummings T, Drolet M, Fairley CK, et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis. 2016;22(10):1732–1740. doi:10.3201/eid2210.160675.
   PubMed Web of Science ®Google Scholar
• Covert C, Ding L, Brown D, Franco EL, Bernstein DI, Kahn JA. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. Hum Vaccin Immunother. 2019;15(7–8):1962–1969. doi:10.1080/21645515.2018.1564438.
   PubMed Web of Science ®Google Scholar
• Saccucci M, Franco EL, Ding L, Bernstein DI, Brown D, Kahn JA. Non-vaccine-type human papillomavirus prevalence after vaccine introduction: no evidence for type replacement but evidence for cross-protection. Sex Transm Dis. 2018;45(4):260–265. doi:10.1097/olq.0000000000000731.
   PubMed Web of Science ®Google Scholar
• Carozzi F, Puliti D, Ocello C, Anastasio PS, Moliterni EA, Perinetti E, Serradell L, Burroni E, Confortini M, Mantellini P, et al. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy. BMC Infect Dis. 2018;18(1):38. doi:10.1186/s12879-018-2945-8.
   PubMedGoogle Scholar
• Dickson EL, Vogel RI, Bliss RL, Downs LS Jr. Multiple-type human papillomavirus (HPV) infections: a cross-sectional analysis of the prevalence of specific types in 309,000 women referred for HPV testing at the time of cervical cytology. Int J Gynecol Cancer. 2013;23(7):1295–1302. doi:10.1097/IGC.0b013e31829e9fb4.
   PubMed Web of Science ®Google Scholar
• Mollers M, Vriend HJ, van der Sande MA, van Bergen JE, King AJ, Lenselink CH, Bekkers RLM, Meijer CJLM, de Melker HE, Bogaards JA, et al. Population- and type-specific clustering of multiple HPV types across diverse risk populations in the Netherlands. Am J Epidemiol. 2014;179(10):1236–1246. doi:10.1093/aje/kwu038.
   PubMed Web of Science ®Google Scholar
• Yang Z, Cuzick J, Hunt WC, Wheeler CM. Concurrence of multiple human papillomavirus infections in a large US population-based cohort. Am J Epidemiol. 2014;180(11):1066–1075. doi:10.1093/aje/kwu267.
   PubMed Web of Science ®Google Scholar
• Man I, Wallinga J, Bogaards JA. Inferring pathogen type interactions using cross-sectional prevalence data: opportunities and pitfalls for predicting type replacement. Epidemiology. 2018;29(5):666–674. doi:10.1097/EDE.0000000000000870.
   PubMed Web of Science ®Google Scholar
• Tota JE, Ramanakumar AV, Jiang M, Dillner J, Walter SD, Kaufman JS, Coutlee F, Villa LL, Franco EL. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol. 2013;178(4):625–634. doi:10.1093/aje/kwt018.
   PubMed Web of Science ®Google Scholar
• Bruni LAG, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. Human papillomavirus and related diseases in the world. ICO/IARC information centre on HPV and cancer (HPV information centre). Summary Report; 2019 Jan 22.
   Google Scholar
• Bruni LAG, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. Human papillomavirus and related diseases in China. ICO/IARC information centre on HPV and cancer (HPV information centre). Summary Report; 2018 Dec 10.
   Google Scholar
• Wei LH, Su YY, Hu YM, Li RC, Chen W, Pan QJ, Zhang X, Zhao F-H, Zhao Y-Q, Li Q, et al. Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18–45 years enrolled in a clinical trial. Clin Microbiol Infect. 2020;26(8):1069–1075. doi:10.1016/j.cmi.2019.12.010.
   PubMed Web of Science ®Google Scholar
• Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M, IARC HPV Prevalence Surveys Study Group. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev. 2010;19(2):503–510. doi:10.1158/1055-9965.EPI-09-0983.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Katki HA, Hildesheim A, Rodriguez AC, Quint W, Schiffman M, Van Doorn L-J, Porras C, Wacholder S, Gonzalez P, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011;203(7):910–920. doi:10.1093/infdis/jiq139.
   PubMed Web of Science ®Google Scholar
• Assmann SF, Hosmer DW, Lemeshow S, Mundt KA. Confidence intervals for measures of interaction. Epidemiology. 1996;7(3):286–290. doi:10.1097/00001648-199605000-00012.
   PubMed Web of Science ®Google Scholar
• Plummer M, Vaccarella S, Franceschi S. Multiple human papillomavirus infections: the exception or the rule? J Infect Dis. 2011;203(7):891–893. doi:10.1093/infdis/jiq146.
   PubMed Web of Science ®Google Scholar
• Nie J, Liu J, Xie H, Sun Z, Zhao J, Chen Q, Liu Y, Huang W, Ruan Q, Wang Y, et al. Multiple human papillomavirus infections and type-competition in women from a clinic attendee population in China. J Med Virol. 2016;88(11):1989–1998. doi:10.1002/jmv.24542.
   PubMed Web of Science ®Google Scholar
• Mejlhede N, Pedersen BV, Frisch M, Fomsgaard A. Multiple human papilloma virus types in cervical infections: competition or synergy? Apmis. 2010;118(5):346–352. doi:10.1111/j.1600-0463.2010.2602.x.
   PubMed Web of Science ®Google Scholar
• Gray P, Palmroth J, Luostarinen T, Apter D, Dubin G, Garnett G, Eriksson T, Natunen K, Merikukka M, Pimenoff V, et al. Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females— post-hoc analysis of a community-randomized clinical trial (II). Int J Cancer. 2018;142(12):2491–2500. doi:10.1002/ijc.31281.
   PubMed Web of Science ®Google Scholar
• Gray P, Luostarinen T, Vanska S, Eriksson T, Lagheden C, Man I, Palmroth J, Pimenoff VN, Söderlund‐Strand A, Dillner J, et al. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: post-hoc analysis of a community randomized clinical trial up to nine years after vaccination (IV). Int J Cancer. 2019;145:785–796. doi:10.1002/ijc.32189.
   PubMed Web of Science ®Google Scholar
• Gargano JW, McClung N, Lewis RM, Park IU, Whitney E, Castilho JL, Pemmaraju M, Niccolai LM, Brackney M, DeBess E, et al. HPV type-specific trends in cervical precancers in the United States, 2008 to 2016. Int J Cancer. 2023;152(2):137–150. doi:10.1002/ijc.34231.
   PubMed Web of Science ®Google Scholar
• Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1274–1280. doi:10.1158/1055-9965.Epi-06-0129.
   PubMed Web of Science ®Google Scholar
• Quint W, Jenkins D, Molijn A, Struijk L, van de Sandt M, Doorbar J, Mols J, Van Hoof C, Hardt K, Struyf F, et al. One virus, one lesion—individual components of CIN lesions contain a specific HPV type. J Pathology. 2012;227(1):62–71. doi:10.1002/path.3970.
   PubMed Web of Science ®Google Scholar
• Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072–1079. doi:10.1093/jnci/dji187.
   PubMedGoogle Scholar
• Yin J, Peng S, Li X, Zhang C, Hu F, Chen W, Qiao Y. Head-to-head comparison of genotyping of human papillomavirus by GP5+/6±PCR-based reverse dot blot hybridization assay and SPF10-PCR-based line probe assay. J Med Virol. 2023;95(2):e28435. doi:10.1002/jmv.28435.
   PubMed Web of Science ®Google Scholar